Member Info for Yorkshirepragma

This 1.3 - 3.9m daily tests .
Assume midpoint ca. 2.5m @5$ profit..
20 % of market achieved?...
...$900m Ann.profit?

From data: range 1-3% of developed world testing /daily.
1.3bn (15%total world pop.)
A lot of rev.

https://ourworldindata.org/grapher/covid-19-daily-tests-vs-daily-new-confirmed-cases-per-million

Based on Noyact monthly rev. Data €25m / month and rising, should Av. Achieve same in due course annual rev. likely @ £200m+/Ann:MCap(conservative X? ) is 1bn
GLA

Times Business...Novocyt testing sales €75m (first 6m) and €25m in June...and increasing.

Been said many times here , but when you hear the rhetoric on the need it’s extraordinarily.

From last two right hand columns .....obtain the no. of ( reported) tests to date...answer...? Alot

https://www.worldometers.info/coronavirus/

https://www.bbc.co.uk/programmes/m000kp68

Insert into interviews ...the value of saliva based test in making step change to process.

Expectation of Cytiva information imminent? R

And this increase gives good estimate . of the relative ‘value’ of Covid testing.
GLA

Times today....testing letdown by slow turnaround....Avacta solution.

Overheard in the Wetherby Whaler...’.done ,with chips‘....

Wiggly,
Congratulations on a factual sensible post.
Only addition is that this make this company an attractive takeover proposition ( at a point).

The question was raised is the science sound here...resoundingly yes. Furthermore having been in the industry( ex Zene..a) I firmly read, the messages after listening to all ( in particular the Avacta,Cytiva teams) as GO.
This is an excellent company. When revenue reaches the likely level of x00m Ann.from the testing element alone then all will be vindicated.
Please read the Sci.Papers .
Regards

But seeking to recruit LFT experienced staff... headhunters our... watch this space I’d suggest!?

And Cytivas team are a highly capable bunch.

Talking Comparable acquisition values ,here’s one from 2019 .GSK taking cancer treat developer Tesoro, with projects ‘in train’...sounds familiar?..
https://www.fiercepharma.com/pharma/checkered-path-a-replay-how-tesaro-got-its-5-1-billion-glaxosmithkline-buyout

Great summary. Having been in the industry it’s only ,message , when all’s done.
The discussion recently online was typical and inter supportive...conclusion soon and certainly positive . The completion of the LFD challenge is just that.

RK, Your comments on the revolution this would create in treatment are well made. Many would benefit. The animal study viewed in the cold would suggest efficacy transfer to man is highly likely. Am sure many in the are will be viewing next stage with interest, and there will be several supporters in train.
Best Regards

RK. It should be banned...some hope tho! Scavengers!

Mstar, your comments on Financials are quite incite full . I hope the Av team take note. Knowing AS I suspect he will have.
A good company with great aims I’d add? Perhaps some Added non scientists would help Strategy.
GLA